Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies ; volume:7 ; number:1 ; day:11 ; month:9 ; year:2019 ; pages:1-18 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (11.9.2019), 1-18, 12.2019
- Creator
-
Mullins, Stefanie R.
Vasilakos, John P.
Deschler, Katharina
Grigsby, Iwen
Gillis, Pete
John, Julius
Elder, Matthew J.
Swales, John
Timosenko, Elina
Cooper, Zachary
Dovedi, Simon J.
Leishman, Andrew J.
Luheshi, Nadia
Elvecrog, James
Tilahun, Ashenafi
Goodwin, Richard
Herbst, Ronald
Tomai, Mark A.
Wilkinson, Robert W.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0724-8
- URN
-
urn:nbn:de:101:1-2020012700180247376870
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mullins, Stefanie R.
- Vasilakos, John P.
- Deschler, Katharina
- Grigsby, Iwen
- Gillis, Pete
- John, Julius
- Elder, Matthew J.
- Swales, John
- Timosenko, Elina
- Cooper, Zachary
- Dovedi, Simon J.
- Leishman, Andrew J.
- Luheshi, Nadia
- Elvecrog, James
- Tilahun, Ashenafi
- Goodwin, Richard
- Herbst, Ronald
- Tomai, Mark A.
- Wilkinson, Robert W.
- SpringerLink (Online service)
Other Objects (12)
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
Deoxyguanosine is a TLR7 agonist
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
Deoxyguanosine is a TLR7 agonist
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
Deoxyguanosine is a TLR7 agonist
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies